UniCycive Therapeutics Inc (UNCY)

[Fred Kadiddlehopper]

I read the 8K a little more cautiously:

Unicycive announced its intention to resubmit the NDA for OLC by year-end, with the potential to receive a new Prescription Drug User Fee Act (PDUFA) date in the first half of 2026. This announcement followed a Type A meeting with the U.S. Food and Drug Administration FDA. During the meeting, the FDA discussed the single deficiency noted in the CRL concerning a third-party manufacturing vendor, with no additional issues identified to the Company, including preclinical, clinical, or safety data. Following the receipt of our CRL in June, our third-party manufacturing vendor was recently inspected by EU regulatory authorities with no deficiencies identified. After the Type A meeting and discussions with our third party manufacturing vendor, we remain optimistic about the resolution of the CRL deficiency and our ability to refile.

The highlighted sentence is ambiguous and could be misleading. A reasonable interpretation of this language could be that:
a.) this manufacturer was inspected by EU regulatory authorities and no deficiencies were found
b.) this EU inspection happened to take place after the CRL was received by UNCY
c.) the EU inspection was not related to the UNCY OCL production, but some other endeavor, but UNCY mgt is pointing to this as evidence that things are well in hand (which I would take with a grain of salt)

I'm assuming this (c.) to be the case since I doubt that EU regulatory authorities are giving an advisory opinion on a product that is not even on their agenda yet.